'Num-chin syndrome', isolated mental neuropathy, is a rare manifestaion of malignant hernatologic diseases, but important sign for early diagnosis and prediction of clinical course and prognosis. Here we report 7 cases of numb-chin syndrome; one in leukemic transformation of malignant lymphoma, one in blastic crisis of chronic myelogenous leukemia and 5 in acute leukemia Two cases of acute leukemia revealed the 'numb-chin sign' in early course of disease before the diagnosis of leukemia and other three in aggravating state of acute leukemia. The therapeutic response and prognosis was poor and 5 cases expired in a few months.
Diagnosis ; Early Diagnosis ; Hematologic Diseases* ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Lymphoma ; Prognosis

A clinicopathological study was made on 17 case with leukemia cutis diagnosed in a period of 10 years frorn 1980 to 1989 in Seoul Xational University I-lospital. The results were summarized as follows : 1. There were 4 cases with acute lyrnphocytic leukernia, 7 with acute myelocytir. leukemia (AML), 5 with chronic myelocytic leukemia (CML), 1 with eosinophilic leukemia. 2. The clinical appearance of leukemia cutis included nodules (88.2%), papules, macules, plaques and ulcerative lesions. Leukemia cutis dis not show any discernible clinical qppearance with each different type of leukemia. 3. Leukemia cutis showed a wide spectrum of histopathologic features, diffuse infiltration, patchy infiltration with linear infiltration between collagen bundles, perivascular and peridnexal involvement, perivascular involvement, and mainly subcutaneous tissue involvement. There was no distinctive histopathologic pattern with each different type of leukemia. 4. The demonstration of intracytoplasmic chloroacetate esterase and lysozyme was helpful to refine the diagnosis of leukemia cutis.
Collagen ; Diagnosis ; Hypereosinophilic Syndrome ; Leukemia* ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Muramidase ; Seoul ; Subcutaneous Tissue ; Ulcer

A 14 years old female patient with chronic myelocytic leukemia was presented. Characteristic blood features of peripheral blood smear and bone marrow findings, clinical symptoms and signs, Philadelphia chromosome are confirmative for the diagnosis of the disease. Pertinent literatures and references were also reviewed briefly.
Adolescent ; Bone Marrow ; Diagnosis ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Leukemia, Myeloid* ; Philadelphia Chromosome*

Adult ; Blast Crisis ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; complications ; diagnosis ; Ulcer ; diagnosis ; etiology

OBJECTIVETo revalidate the conversion factor（CF）for the conversion of BCR-ABL （P210）transcript levels to the international scale（BCR- ABLIS）in chronic myeloid leukemia（CML） which validated before.

METHODSPeking University People's Hospital（PKUPH）prepared the exchange samples for revalidation of CFs of 15 laboratories which validated nine or eighteen months ago. The fresh BCR-ABL（P210）（+）bone morrow or peripheral blood nucleated cells were diluted with BCR-ABL （P210）（-）cells to achieve different BCR- ABL levels, totally 16 sets and 24 samples per set were prepared. TRIzol reagent was added in each tube. Each laboratory tested BCR-ABL transcript levels of one set of samples. Agreement between BCR-ABLIS of each laboratory and PKUPH was assessed by the Bland- Altman method. For laboratories which did not meet the criteria of revalidation, linear regression equation was derived after the samples with maximum BCR-ABL deviation were removed until R²>0.98, then new CF was calculated.

RESULTS10 laboratories met the revalidation criteria with both bias within ±1.4 fold and 95% limits of agreement within ±6 folds, and their CFs still could be used for accurately conversion of BCR-ABLIS. New CFs were recalculated as of 1.8-6.3 folds of their previous CFs in 5 laboratories not met the criteria.

CONCLUSIONRevalidation of CF by sample exchange among laboratories was necessary for accurate and continuous application of BCR-ABLIS, which not only tested the validity of CF acquired before but also calculated new available CFs for those with invalid CFs.

China ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; therapy ; Practice Guidelines as Topic

There have been few cases of Neurofibromatosis associated with Chronic Myelocytic Leukemia in literature and we found only one report in Korea which described the association of Chronic Myelocytic Leukemia with Neurofibromatosis. We report a case of patient whose clinical and hematological findings were compatible with Chronic Myelocytic Leukemia and Neurofibromatosis. Busulfan was used in the treatment of this patient followed by some degree of remission. A brief review of literature supporting our diagnosis was included in this report.
Busulfan ; Diagnosis ; Humans ; Korea ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive* ; Neurofibromatoses*

Adult ; China ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; therapy

Child ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; complications ; diagnosis ; Male ; Priapism ; etiology ; surgery

All kinds of tumors have their specific DNA methylation patterns. The study of DNA methylation changes in chronic myelogenous leukemia includes (1) the hypomethylation of carcinogenic gene, (2) the hypermethylation of tumor-suppressing gene, and (3) the hypermethylation of fusion gene. In this paper, DNA methylation change in chronic myeloid leukemia (CML) and its role in clinical stages and evaluation of prognosis were reviewed so as to illuminate the relationship between DNA methylation and CML.
DNA Methylation ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; genetics ; pathology ; Prognosis